Back to Search
Start Over
Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A.
- Source :
-
Theranostics [Theranostics] 2021 Jan 01; Vol. 11 (1), pp. 117-131. Date of Electronic Publication: 2021 Jan 01 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Background: Tertiary lymphoid organs (TLOs) occur after multiple chronic kidney injuries. interleukin-17A (IL-17A) has been reported to associate with the development of TLOs in inflammatory diseases. However, regulation of the renal TLOs and its clinical significance to the pathogenesis of chronic kidney injury are unknown. Methods: To evaluate the clinical significance and regulation of renal TLOs, we analyzed the progression of patients with kidney damage based on the existence and absence of TLOs in a larger multicenter cohort. We also blocked the recruitment of lymphocyte cells into the kidney by FTY720 (fingolimod) in vivo . Besides, we used aged IL-17A genetic knocked out mice and IL-17A-neutralizing antibody to explore the role of IL-17A in renal TLOs formation. Results : We demonstrated that renal TLOs of IgA nephropathy patients were associated with disease severity and were independent risk factors for renal progression after adjustment for age, sex, mean arterial pressure, proteinuria and, baseline eGFR and MEST-C score, especially in the early stage. Plasma levels of TLO-related chemokines CXCL13, CCL19, and CCL21 were higher in patients with renal TLOs. Inhibiting the formation of renal TLOs by FTY720 could reduce the intrarenal inflammation and fibrosis, and early intervention was found to be more effective. IL-17A was increased in renal TLOs models, and genetic depletion of IL-17A or treatment with anti-IL-17A antibody resulted in a marked reduction of the TLOs formation as well as alleviation of renal inflammation and fibrosis. Conclusion: These results indicate that TLOs are associated with the progression of kidney damage and regulated by IL-17A and may be effective targets for the treatment of kidney damage.<br />Competing Interests: Competing Interests: The authors have declared that no competing interest exists.<br /> (© The author(s).)
- Subjects :
- Adult
Animals
Disease Progression
Female
Fingolimod Hydrochloride pharmacology
Glomerulonephritis, IGA immunology
Glomerulonephritis, IGA pathology
Glomerulonephritis, Membranous immunology
Glomerulonephritis, Membranous pathology
Humans
Immunosuppressive Agents pharmacology
Kidney drug effects
Kidney immunology
Lupus Nephritis immunology
Lupus Nephritis pathology
Male
Mice
Mice, Knockout
Middle Aged
Nephrosis, Lipoid immunology
Nephrosis, Lipoid pathology
Renal Insufficiency, Chronic immunology
Tertiary Lymphoid Structures genetics
Tertiary Lymphoid Structures immunology
Interleukin-17 genetics
Kidney pathology
Renal Insufficiency, Chronic pathology
Tertiary Lymphoid Structures pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1838-7640
- Volume :
- 11
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Theranostics
- Publication Type :
- Academic Journal
- Accession number :
- 33391465
- Full Text :
- https://doi.org/10.7150/thno.48624